Ra Capital Management, L.P. 4 D Molecular Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.17 Billion
- Q4 2024
A detailed history of Ra Capital Management, L.P. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 4,563,211 shares of FDMT stock, worth $20.7 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
4,563,211
Previous 5,098,211
10.49%
Holding current value
$20.7 Million
Previous $55.1 Million
53.88%
% of portfolio
0.41%
Previous 0.77%
Shares
6 transactions
Others Institutions Holding FDMT
# of Institutions
147Shares Held
46.7MCall Options Held
121KPut Options Held
33.2K-
Black Rock Inc. New York, NY4.9MShares$22.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.27MShares$19.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.95MShares$13.4 Million2.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$13 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.67MShares$12.1 Million0.56% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $147M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...